Toxicological assessment of gadoversetamide injection (OptiMARK®), a new contrast-enhancement agent for use in magnetic resonance imaging

Investigative Radiology

Volumn 36, Issue 7, 2001, Pages 401-412

  Wible, James H ^a   Troup, Catherine M ^a   Hynes, Michael R ^a   Galen, Karen P ^a   MacDonald, Janice R ^a   Barco, Steven J ^a   Wojdyla, Jolette K ^a   Periasamy, M Peri ^a   Adams, Max D ^a  

^a MALLINCKRODT PHARMACEUTICALS   (United States)

Author keywords

Gadoversetamide injection; MR image enhancement; Preclinical safety; Toxicity

Indexed keywords

CONTRAST MEDIUM; GADOVERSETAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EFFECT; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOG; DRUG REEXPOSURE; DRUG SAFETY; FEMALE; FETUS; GENETIC TOXICOLOGY; LETHAL DOSE; MALE; MOUSE; MUTAGENICITY; NEWBORN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RABBIT; RAT; REPRODUCTIVE TOXICITY; TERATOGENICITY; TOXICITY TESTING;

EID: 0034947592     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-200107000-00006     Document Type: Article

References (16)

1. Chemical synthesis of paramagnetic complexes
2. Feasibility and utility of respiratory-gated, gadolinium-enhanced T1-weighted magnetic resonance urography in children
3. Safety and efficacy of Omniscan® (gadodiamide injection) at 0.1 mmol/kg for MRI in infants younger than 6 months of age: Phase III open multicenter study
4. Magnetic resonance imaging in patients with central nervous system pathology: A comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (GD-DTPA)
5. A multicenter, randomized double-blind study to evaluate the safety, tolerability and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: Results of a Phase III clinical trial
6. A computer program for estimating LD50 and its confidence limits using modified Behrens-Reed-Muench cumulant method
7. Summary of preclinical safety evaluation of gadoteridol injection
8. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent
9. Motor coordination testing of the neurotoxicity of paramagnetic chelates
10. DV-7572 injection toxicity to rats by repeated intravenous injection for 4 weeks followed by a 4 week recovery period
11. Contrast media-induced renal tubular vacuolization: A light and electron microscopic study on rat kidneys
12. Contrast media-induced renal tubular vacuolization after dehydration: A light and electron microscopic study in rats
13. Safety, tolerance and pharmacokinetics of high doses of gadodiamide injection, a non-ionic magnetic resonance imaging contrast agent
14. Interference of gadodiamide injection (Omniscan®) on the colorimetric determination of serum calcium
15. Testicular damage associated with zinc deficiency in pre- and post-pubertal rats: Response to zinc repletion
16. Severe zinc deficiency in male and female rats